StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.92+0.22 (+3.86%)

Close on Nov 18, 2026Market cap $769.50MP/E –Yield –

Cytek Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Cytek Biosciences's revenue for the twelve months ending Jun 30, 2026 was $206.71M, up 5.4% year over year. For fiscal 2025 it was $201.49M, up 0.5% from the year before. The highest annual figure on record is $201.49M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$201.49M+0.5%
FY2024Dec 31, 2024$200.45M+3.9%
FY2023Dec 31, 2023$193.02M+17.7%
FY2022Dec 31, 2022$164.04M+7421.1%
FY2021Dec 31, 2021$2.18M+207.2%
FY2020Dec 31, 2020$710.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$48.14M+5.6%
Q1 FY2026Mar 31, 2026$44.14M+6.5%
Q4 FY2025Dec 31, 2025$62.14M+8.1%
Q3 FY2025Sep 30, 2025$52.29M+1.5%
Q2 FY2025Jun 30, 2025$45.60M-2.2%
Q1 FY2025Mar 31, 2025$41.46M-7.6%
Q4 FY2024Dec 31, 2024$57.48M-1.3%
Q3 FY2024Sep 30, 2024$51.50M+7.3%
Q2 FY2024Jun 30, 2024$46.62M-6.2%
Q1 FY2024Mar 31, 2024$44.86M+21.0%
Q4 FY2023Dec 31, 2023$58.23M+20.5%
Q3 FY2023Sep 30, 2023$48.00M+18.6%
Q2 FY2023Jun 30, 2023$49.69M+23.7%
Q1 FY2023Mar 31, 2023$37.09M+5.8%
Q4 FY2022Dec 31, 2022$48.34M+24.3%
Q3 FY2022Sep 30, 2022$40.48M+17.7%
Q2 FY2022Jun 30, 2022$40.16M+32.1%
Q1 FY2022Mar 31, 2022$35.06M+44.5%
Q4 FY2021Dec 31, 2021$38.89M+27.0%
Q3 FY2021Sep 30, 2021$34.38M+37.0%
Q2 FY2021Jun 30, 2021$30.41M+58.9%
Q1 FY2021Mar 31, 2021$24.27M–
Q4 FY2020Dec 31, 2020$30.62M–
Q3 FY2020Sep 30, 2020$25.10M–
Q2 FY2020Jun 30, 2020$19.14M–

More Cytek Biosciences figures

See a number that looks wrong?